Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries

Cancer

Volumn 118, Issue 3, 2012, Pages 681-688

  Ryan, Paul ^a,b   Mulligan, Anna Marie ^c   Aronson, Melyssa ^a   Ferguson, Sarah E ^d   Bapat, Bharati ^a   Semotiuk, Kara ^a   Holter, Spring ^a   Kwon, Janice ^e   Kalloger, Steve E ^e   Gilks, C Blake ^e   Gallinger, Steven ^f   Pollett, Aaron ^a   Clarke, Blaise A ^g  

^a MOUNT SINAI HOSPITAL   (Canada)

^b BON SECOURS HOSPITAL   (Ireland)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

clinical screening; endometrial cancer; Lynch syndrome; microsatellite instability; mismatch repair

Indexed keywords

MISMATCH REPAIR PROTEIN;

ADULT; ANAMNESIS; ARTICLE; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MMR GENE; PEDIGREE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CYSTADENOCARCINOMA, SEROUS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PEDIGREE; PROGNOSIS; REGISTRIES;

EID: 80052996018     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26323     Document Type: Article

References (39)

1. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96: 261-268.
2. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998; 338: 1481-1487.
3. Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet. 2001; 69: 780-790.
4. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000; 18: 2193-2200.
5. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352: 1851-1860.
6. Hampel H, Panescu J, Lockman J, et al. Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2007; 67: 9603.
7. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999; 81: 214-218.
8. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997; 6: 105-110.
9. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005; 105: 569-574.
10. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009; 11: 35-41.
11. Bonis PA, Trikalinos TA, Chung M, et al. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evidence Report/Technology Assessment No. 150. AHRQ Publication No. 07-E008. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
12. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN,. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009; 11: 42-65.
13. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997; 89: 1758-1762.
14. Vasen HF, Mecklin JP, Khan PM, Lynch HT,. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991; 34: 424-425.
15. Vasen HF, Watson P, Mecklin JP, Lynch HT,. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999; 116: 1453-1456.
16. Greenson JK, Huang SC, Herron C, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009; 33: 126-133.
17. Jenkins MA, Hayashi S, O'shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007; 133: 48-56.
18. Movahedi-Lankarani S, Gilks CB, Soslow R, et al. Protocol for the Examination of Specimens from Patients with Carcinoma of the Endometrium. Northfield, IL: College of American Pathologists (CAP) Press; 2009.
19. Boland CR, Shike M,. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer [serial online]. Gastroenterology. 2010; 138: 2197.e1-e7.
20. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66: 7810-7817.
21. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007; 107: 159-162.
22. Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009; 33: 925-933.
23. Shia J, Black D, Hummer AJ, Boyd J, Soslow RA,. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008; 39: 116-125.
24. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008; 26: 5965-5971.
25. Garg K, Soslow RA,. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol. 2009; 62: 679-684.
26. Woods MO, Hyde AJ, Curtis FK, et al. High frequency of hereditary colorectal cancer in Newfoundland likely involves novel susceptibility genes. Clin Cancer Res. 2005; 11: 6853-6861.
27. de Leeuw WJ, Dierssen J, Vasen HF, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol. 2000; 192: 328-335.
28. Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol. 2003; 21: 4364-4370.
29. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007; 25: 5158-5164.
30. Boks DE, Trujillo AP, Voogd AC, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer. 2002; 102: 198-200.
31. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010; 102: 193-201.
32. Palacios J, Alenda C, Lujan D, et al. Pathological features of endometrial cancer in patients with Lynch syndrome [abstract]. Lab Invest. 2010; 90 (suppl 1). Abstract 258A.
33. Honore LH, Hanson J, Andrew SE,. Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables. Int J Gynecol Cancer. 2006; 16: 1386-1392.
34. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006; 106: 87-94.
35. Carcangiu ML, Radice P, Casalini P, et al. Lynch syndrome-related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int J Surg Pathol. 2010; 18: 21-26.
36. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths [serial online]. Am J Obstet Gynecol. 2008; 198: 218.e1-e6.
37. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA,. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently under recognized neoplasms. Mod Pathol. 2010; 23: 781-789.
38. Resnick K, Straughn JM Jr, Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol. 2009; 114: 530-536.
39. Resnick KE, Hampel H, Fishel R, Cohn DE,. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009; 114: 128-134.